Biogenerics After All? US FDA Wants Biosimilar Process To Mirror Generics

 
• By Ramsey Baghdadi
  
US FDA seems poised to move away from the ‘quite burdensome’ testing framework it currently uses for biosimilars. (Shutterstock)

More from Biosimilars

More from Biosimilars & Generics